Skip to content

Generation of induced pluripotent stem cell (iPSC) and druggability studies of their derived cells

Generation of induced pluripotent stem cell (iPSC) and druggability studies of their derived cells

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300069332
Enrollment
Unknown
Registered
2023-03-13
Start date
2023-03-13
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, liver disease, etc.

Interventions

Sponsors

Shenzhen Hospital of Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1. Healthy subjects, male or female; 2. Individuals who are 18 to 35 (including 18 and 35) years old, have the capacity to act independently, and provide the signed informed consent; 3. Negative for HIV1/2, HBV, HCV, HTLV1/2, HEBV, HCMV, TP, B19, HAV, HHV6/7/8 antibody (or antigen) or nucleic acid tests; 4. Negative for COVID-19 nucleic acid test; 5. The counts of red blood cells, white blood cells, and platelets are normal; 6. Normal liver function (3 items: ALT, AST, serum total bilirubin); 7. Normal renal function (4 items: urea, creatinine, uric acid); 8. Normal level of serum tumor markers (9 items: AFP, CEA, CA19-9, CA125, CA15-3, SCC, CYK-19/CYFRA21-1, ProGRP, NSE); 9. Normal blood lipids level (4 items: TC, TG, HDL-C, LDL-C); 10. Normal blood glucose level (2 items: Fasting glucose, glycated hemoglobin); 11. Normal karyotype of the peripheral blood cells.

Exclusion criteria

Exclusion criteria: 1. Women under pregnancy or breastfeeding; 2. With clinically abnormalities in physical examination, electrocardiography, laboratory tests, and vital signs; 3. Has family history of inherited disease; 4. Has been diagnosed with cancer; 5. Has been diagnosed with disorders in cardiovascular, endocrine, urinary, neurologic, respiratory, blood, immune (including personal or inherited immunodeficiency), psychiatric, metabolic system; and now still has the clinically relevant abnormalities; 6. Has a history of tuberculosis infection; 7. With Creutzfeldt-Jakob disease, or their family members has a history of Creutzfeldt-Jakob disease; 8. With infectious diseases; 9. With parasitic disease; 10. Long-term use of corticosteroids, immunosuppressants, sedation, psychotropic drugs. Or drug dependence, alcohol dependence, or substance abuse, no matter previous or current; 11. Recipients of allogeneic tissue or organ transplantation; 12. Received surgery for removal of major organs (such as stomach, kidney, and spleen); 13. Have been vaccinated with rabies vaccine or hepatitis B immune globulin within 1 year before the trial, or other vaccines within 1 month; 14. Those who cannot tolerate venipuncture or have a history of blood sickness or needle sickness; 15. Not suitable to participate the trial according to the investigator's judgment.

Design outcomes

Primary

MeasureTime frame
Age;Health status;

Countries

China

Contacts

Public ContactXu Xueqing

Shenzhen Hospital of Southern Medical University

chubuyi@qq.com+86 138 2337 7457

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026